97426-53-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-METHYLPHENYL)ETHANETHIOAMIDE is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable component in the development of new drugs.
Used in Antibacterial Applications:
2-(4-METHYLPHENYL)ETHANETHIOAMIDE is used as an antibacterial agent for the treatment of bacterial infections. Its antibacterial properties have been studied, and it has shown potential in combating various types of bacterial infections.
Safety Precautions:
2-(4-METHYLPHENYL)ETHANETHIOAMIDE should be handled and used with proper safety precautions due to its potential health hazards. It is important to follow all recommended guidelines and protocols to ensure the safety of individuals working with this chemical compound.

InChI:InChI=1/C9H11NS/c1-7-2-4-8(5-3-7)6-9(10)11/h2-5H,6H2,1H3,(H2,10,11)

Upstream product

• 6212-86-8 2-(p-tolyl)acetamide 
• 35675-44-6 4-methylphenylacetyl chloride 
• 622-97-9 1-ethenyl-4-methylbenzene 
• 104-81-4 4-Methylbenzyl bromide 
• 2947-61-7 (4-methylphenyl)acetonitrile 

Relevant academic research and scientific papers

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Thioamide derivative and preparation method thereof

The invention discloses a thioamide derivative. The structural formula of the thioamide derivative is represented by the formula (I) or the formula (II). The invention also provides a preparation method of the thioamide derivative. According to the preparation method, alkali metal salts are taken as the alkalis, amines are directly coupled with alkenes and sulfur, and by selecting the alkali, twodifferent thioamide derivatives represented by the formula (I) and the formula (II) can be prepared from same raw materials. The provided preparation method has the advantages that the raw materials are cheap and easily available, the synthesis method is simple, and the cost is largely reduced. The provided thioamide derivatives can be used in fields such as bioactive molecules, drug synthesis, and the like, and has a wide application range.

Base-Controlled Three Component Reactions of Amines, Elemental Sulfur, and Styrenes: Synthesis of Thioamides under Metal-Free Conditions

Three component reactions of olefins, amines, and sulfur were studied. Thioamidation of styrenes is base-controlled, and 2-phenylethanethioamides and benzothioamides were obtained selectively in the presence of two different bases. This protocol offers a simple and efficient procedure for the synthesis of thioamides.

Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1

Structure-activity relationships of three related series of 4-phenylthiazol-5-ylacetic acids, derived from two hits emanating from a focused library obtained by in silico screening, have been explored as CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) antagonists. Several compounds with double digit nanomolar binding affinity and full antagonistic efficacy for human CRTH2 receptor were obtained in all subclasses. The most potent compound was [2-(4-chloro-benzyl)-4-(4-phenoxy-phenyl)-thiazol-5-yl]acetic acid having an binding affinity of 3.7 nM and functional antagonistic effect of 66 nM in a BRET and 12 nM in a cAMP assay with no functional activity for the other PGD2 DP receptor (27 μM in cAMP).